Trial · NCT02066532
Adverse events123
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 123
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pain in extremity | General disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Muscle weakness, upper limb | Musculoskeletal and connective tissue disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Anemia | Blood and lymphatic system disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 14 | 26 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 2 | 26 | |
| other | Urinary Incontinence | Renal and urinary disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Eye Disorder | Eye disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 2 | 26 | |
| other | Abdominal Pain | Gastrointestinal disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Alanine aminotransferase increase | Blood and lymphatic system disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 5 | 26 | |
| other | Alkaline phosphatase increased | Blood and lymphatic system disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 4 | 26 | |
| other | Allergic rhinitis | Immune system disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 2 | 26 | |
| other | Anorexia | Metabolism and nutrition disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 2 | 26 | |
| other | Anxiety | Psychiatric disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Ascites | General disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Aspartate aminotransferase increase | Blood and lymphatic system disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 8 | 26 | |
| other | Bloating | Gastrointestinal disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 3 | 26 | |
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 5 | 26 | |
| other | Blood bilirubin increased | Blood and lymphatic system disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 1 | 26 | |
| other | Blurred vision | Eye disorders | Phase 1 and 2: Ruxolitinib/Trastuzumab (25 mg) | 3 | 26 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02066532/events